69 related articles for article (PubMed ID: 18465557)
1. Diarylsulfonylureas--a new class of antitumor agents.
Guan X
IDrugs; 1998 Jul; 1(3):334-8. PubMed ID: 18465557
[TBL] [Abstract][Full Text] [Related]
2. Effect of albumin on antitumor activity of diarylsulfonylureas.
Schultz RM; Andis SL; Toth JE; Boder GB; Rinzel SM; Grindey GB
Anticancer Res; 1993; 13(6A):1939-43. PubMed ID: 8297099
[TBL] [Abstract][Full Text] [Related]
3. [The structure and antitumor activity of antitumor antibiotics--recent progress].
Otake N
Gan To Kagaku Ryoho; 1988 Mar; 15(3):369-79. PubMed ID: 3279909
[TBL] [Abstract][Full Text] [Related]
4. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
5. Nitrosoureas: a review of experimental antitumor activity.
Schabel FM
Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
[TBL] [Abstract][Full Text] [Related]
6. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
7. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
[TBL] [Abstract][Full Text] [Related]
8. [Camptothecin and derivatives: a new class of antitumor agents].
Torck M; Pinkas M
J Pharm Belg; 1996; 51(4):200-7. PubMed ID: 8965250
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
10. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
11. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro.
Sebolt JS; Scavone SV; Pinter CD; Hamelehle KL; Von Hoff DD; Jackson RC
Cancer Res; 1987 Aug; 47(16):4299-304. PubMed ID: 2440564
[TBL] [Abstract][Full Text] [Related]
12. Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity.
Nakagawa-Goto K; Bastow KF; Chen TH; Morris-Natschke SL; Lee KH
J Med Chem; 2008 Jun; 51(11):3297-303. PubMed ID: 18473435
[TBL] [Abstract][Full Text] [Related]
13. Glutathione-dependent metabolism of the antitumor agent sulofenur. Evidence for the formation of p-chlorophenyl isocyanate as a reactive intermediate.
Jochheim CM; Davis MR; Baillie KM; Ehlhardt WJ; Baillie TA
Chem Res Toxicol; 2002 Feb; 15(2):240-8. PubMed ID: 11849051
[TBL] [Abstract][Full Text] [Related]
14. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.
Finch RA; Shyam K; Penketh PG; Sartorelli AC
Cancer Res; 2001 Apr; 61(7):3033-8. PubMed ID: 11306484
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using the fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells.
Fridborg H; Nygren P; Dhar S; Csoka K; Kristensen J; Larsson R
J Exp Ther Oncol; 1996 Sep; 1(5):286-95. PubMed ID: 9414416
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
17. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles.
Hawkins MJ
Oncology (Williston Park); 1992 Dec; 6(12):17-23; discussion 27-30. PubMed ID: 1361358
[TBL] [Abstract][Full Text] [Related]
18. Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions.
Thakar JH; Chapin C; Berg RH; Ashmun RA; Houghton PJ
Cancer Res; 1991 Dec; 51(23 Pt 1):6286-91. PubMed ID: 1933889
[TBL] [Abstract][Full Text] [Related]
19. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
Schabel FM; Trader MW; Laster WR; Corbett TH; Griswold DP
Cancer Treat Rep; 1979; 63(9-10):1459-73. PubMed ID: 291480
[TBL] [Abstract][Full Text] [Related]
20. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
